{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T10:13:09Z","timestamp":1698833589348},"reference-count":41,"publisher":"Akademiai Kiado Zrt.","issue":"9","license":[{"start":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:00:00Z","timestamp":1614470400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,2,28]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold> A Bruton-f\u00e9le tirozin-kin\u00e1zt g\u00e1tl\u00f3 ibrutinib \u00e9s a\n                    B-sejtes lymphoma-2-t g\u00e1tl\u00f3 venetoklax a kr\u00f3nikus lymphoid leukaemia (CLL)\n                    kezel\u00e9s\u00e9nek egyre kor\u00e1bbi vonal\u00e1ban alkalmazhat\u00f3, \u00e9s ezek mellett a\n                    progresszi\u00f3mentes t\u00fal\u00e9l\u00e9s n\u00f6veked\u00e9se figyelhet\u0151 meg. A c\u00e9lzott kismolekul\u00e1kkal\n                    v\u00e9gzett kezel\u00e9s nemcsak a CLL lefoly\u00e1s\u00e1t, de a betegek gondoz\u00e1s\u00e1t is alapvet\u0151en\n                    megv\u00e1ltoztatta. A tart\u00f3san adagolt or\u00e1lis szerek mellett a betegek nagyobb\n                    val\u00f3sz\u00edn\u0171s\u00e9ggel jelennek meg a panaszaiknak megfelel\u0151 szakrendel\u00e9seken. Az \u00faj\n                    t\u00edpus\u00fa szerek hat\u00e1sai \u00e9s mell\u00e9khat\u00e1sai mellett az alapvet\u0151\n                    gy\u00f3gyszer-interakci\u00f3kra is fel kell h\u00edvni a figyelmet. Kiemelt fontoss\u00e1g\u00fa az\n                    ibrutinib hypertoni\u00e1t provok\u00e1l\u00f3 hat\u00e1sa, illetve a 6\u201316%-ban megjelen\u0151\n                    pitvarfibrill\u00e1ci\u00f3. Ez ut\u00f3bbi ell\u00e1t\u00e1s\u00e1t a gy\u00f3gyszer-interakci\u00f3kon t\u00fal az\n                    ibrutinib v\u00e9rz\u00e9kenys\u00e9get okoz\u00f3 hat\u00e1sa is nehez\u00edti. A CLL-lel, illetve annak\n                    kezel\u00e9s\u00e9vel kapcsolatos ismeretek a m\u00e1sodlagos daganatok, n\u00e9h\u00e1ny\n                    gastrointestinalis \u00e9s b\u0151rgy\u00f3gy\u00e1szati betegs\u00e9g megk\u00f6zel\u00edt\u00e9se szempontj\u00e1b\u00f3l is\n                    fontosak. A venetoklax mellett potenci\u00e1lisan kialakul\u00f3 tumorl\u00edzis-szindr\u00f3ma\n                    alkalmank\u00e9nt a nefrol\u00f3gusok bevon\u00e1s\u00e1t ig\u00e9nyli. A betegek gondoz\u00e1sa, megfelel\u0151\n                    szakszer\u0171 ell\u00e1t\u00e1sa \u00e9s a betegutak optimaliz\u00e1l\u00e1sa \u00e9rdek\u00e9ben a h\u00e1ziorvosok, a\n                    s\u00fcrg\u0151ss\u00e9gi ell\u00e1t\u00f3k \u00e9s az egy\u00e9b szakell\u00e1t\u00f3 helyek szoros egy\u00fcttm\u0171k\u00f6d\u00e9se sz\u00fcks\u00e9ges\n                    szakorvosi konzult\u00e1ci\u00f3 keretei k\u00f6z\u00f6tt. Orv Hetil. 2021; 162(9): 336\u2013343.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold> Chronic lymphocytic leukemia (CLL) is ubiquitously treated\n                    with novel agents. The Bruton\u2019s tyrosine kinase inhibitor ibrutinib and the\n                    B-cell lymphoma 2 inhibitor venetoclax can be used increasingly in earlier lines\n                    of treatment with improved progression-free survival. Treatment with targeted\n                    small molecules fundamentally changed not only the course of CLL but also the\n                    care of patients. With the administration of long-term oral medications,\n                    patients are more likely to show up at specialist clinics that match their\n                    complaints. In addition to the effects and side effects of the new drugs,\n                    attention should also be drawn to basic drug interactions. The effect of\n                    ibrutinib on blood pressure and the ability to provoke atrial fibrillation in\n                    6\u201316% of cases are of paramount importance. In addition to drug interactions,\n                    the treatment of the latter is also complicated by the hemorrhagic effect of\n                    ibrutinib. Knowledge on CLL and its treatment is also important in the approach\n                    to secondary tumors, some gastrointestinal and dermatological diseases. The\n                    potential for tumor lysis syndrome of venetoclax requires close collaboration\n                    with nephrologists. In order to provide appropriate professional care and\n                    optimize patient pathways, close co-operation between GPs, emergency care\n                    providers and other specialist care facilities is required within the framework\n                    of professional consultation. Orv Hetil. 2021; 162(9): 336\u2013343.<\/jats:p>","DOI":"10.1556\/650.2021.31948","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T12:09:37Z","timestamp":1617106177000},"page":"336-343","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":0,"title":["A kr\u00f3nikus lymphoid leukaemia mai kezel\u00e9s\u00e9nek interdiszciplin\u00e1ris k\u00e9rd\u00e9sei"],"prefix":"10.1556","volume":"162","author":[{"given":"R\u00f3bert","family":"Sz\u00e1sz","sequence":"first","affiliation":[{"name":"1 Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati Int\u00e9zet, Hematol\u00f3giai Tansz\u00e9k, Debrecen, Nagyerdei krt. 98., 4032"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[{"name":"1 Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati Int\u00e9zet, Hematol\u00f3giai Tansz\u00e9k, Debrecen, Nagyerdei krt. 98., 4032"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1 Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116: 3724-3734. [Erratum: Blood 2011; 117: 3477.]","DOI":"10.1182\/blood-2010-05-282632"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2 Hern\u00e1ndez JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer 1995; 75(1 Suppl): 381-394.","DOI":"10.1002\/1097-0142(19950101)75:1+<381::AID-CNCR2820751320>3.0.CO;2-B"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"3 Siegel","year":"2020","unstructured":"3 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70: 7-30.","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4 Gurbity P\u00e1lfi T, F\u00e9s\u00fcs V, B\u00f6d\u00f6r C, et al. State of the art molecular diagnostics and therapy of chronic lymphocytic leukaemia in the era of new targeted therapies. [A kr\u00f3nikus lymphocyt\u00e1s leukaemia korszer\u0171 molekul\u00e1ris diagnosztik\u00e1ja \u00e9s kezel\u00e9se az \u00faj c\u00e9lzott ter\u00e1pi\u00e1k korszak\u00e1ban.] Orv Hetil. 2017; 158: 1620-1629. [Hungarian]","DOI":"10.1556\/650.2017.30870"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1182\/blood.V126.23.2933.2933","article-title":"Atrial fibrillation in CLL\/SLL patients on ibrutinib","volume":"126","author":"5 Farooqui","year":"2015","unstructured":"5 Farooqui M, Valdez J, Soto S, et al. Atrial fibrillation in CLL\/SLL patients on ibrutinib. Blood 2015; 126: 2933-2933.","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"6 Burger","year":"2015","unstructured":"6 Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015; 373: 2425-2437.","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"7 Byrd","year":"2014","unstructured":"7 Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371: 213-223.","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"8 McMullen","year":"2014","unstructured":"8 McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014; 124: 3829-3830.","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1073\/pnas.0606663104","article-title":"Protective effects of exercise and phosphoinositide 3-kinase(p110\u03b1) signaling in dilated and hypertrophic cardiomyopathy","volume":"104","author":"9 McMullen","year":"2007","unstructured":"9 McMullen JR, Amirahmadi F, Woodcock EA, et al. Protective effects of exercise and phosphoinositide 3-kinase(p110\u03b1) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 2007; 104: 612-617.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10 Ezeani M, Elom S. Necessity to evaluate PI3K\/Akt signalling pathway in proarrhythmia. Open Heart 2017; 4: e000596.","DOI":"10.1136\/openhrt-2017-000596"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"11 Ganatra","year":"2018","unstructured":"11 Ganatra S, Sharma A, Shah S, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018; 4: 1491-1500.","journal-title":"JACC Clin Electrophysiol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"12 Shatzel","year":"2017","unstructured":"12 Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017; 15: 835-847.","journal-title":"J Thromb Haemost"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/leu.2016.316","article-title":"Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib","volume":"31","author":"13 Kazianka","year":"2017","unstructured":"13 Kazianka L, Drucker C, Skrabs C, et al. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia 2017; 31: 1117-1122.","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"14 Kamel","year":"2015","unstructured":"14 Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 2015; 29: 783-787.","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"15 Levade","year":"2014","unstructured":"15 Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood 2014; 124: 3991-3995.","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"16 Wang","year":"2015","unstructured":"16 Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126: 739-745.","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial","volume":"387","author":"17 Baharoglu","year":"2016","unstructured":"17 Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 2016; 387: 2605-2613.","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"18 Byrd","year":"2015","unstructured":"18 Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015; 125: 2497-2506.","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"19 Chai-Adisaksopha","year":"2014","unstructured":"19 Chai-Adisaksopha C, Crowther M, Isayama T, et al. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124: 2450-2458.","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","article-title":"Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment","volume":"41","author":"20 Burnett","year":"2016","unstructured":"20 Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016; 41: 206-232.","journal-title":"J Thromb Thrombolysis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3960\/jslrt.18012","article-title":"A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment","volume":"58","author":"21 Suzuki","year":"2018","unstructured":"21 Suzuki T, Miyakoshi S, Nanba A, et al. A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment. J Clin Exp Hematop. 2018; 58: 136-140.","journal-title":"J Clin Exp Hematop"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"742146","DOI":"10.1155\/2008\/742146","article-title":"Colonic involvement in a patient with chronic lymphocytic leukaemia","volume":"2008","author":"22 Arkkila","year":"2008","unstructured":"22 Arkkila PE, Nuutinen H, Ebeling F, et al. Colonic involvement in a patient with chronic lymphocytic leukaemia. Gastroenterol Res Pract. 2008; 2008: 742146.","journal-title":"Gastroenterol Res Pract"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23 Green M, Abuamr KM. Chronic lymphocytic leukemia manifesting as colon polyps. Program No. P1543. ACG 2018 Annual Scientific Meeting Abstracts. American College of Gastroenterology, Philadelphia, PA. Am J Gastroenterol. 2018; 113(Suppl 1): 888.","DOI":"10.14309\/00000434-201810001-01543"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","article-title":"Idelalisib-associated colitis: histologic findings in 14 patients","volume":"39","author":"Weidner A-S","year":"2015","unstructured":"24 Weidner A-S, Panarelli NC, Geyer JT, et al. Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol. 2015; 39: 1661-1667.","journal-title":"Am J Surg Pathol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00280-015-2708-9","article-title":"The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia","volume":"75","author":"Jong J","year":"2015","unstructured":"25 de Jong J, Sukbuntherng J, Skee D, et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2015; 75: 907-916.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1182\/blood.V128.22.1588.1588","article-title":"An open-label, sequential-design drug interaction study of the effects of omeprazole on the pharmacokinetics of ibrutinib in healthy adults","volume":"128","author":"Jong J","year":"2016","unstructured":"26 de Jong J, Hellemans P, Jiao J, et al. An open-label, sequential-design drug interaction study of the effects of omeprazole on the pharmacokinetics of ibrutinib in healthy adults. Blood 2016; 128: 1588.","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"27 Hallek","year":"2018","unstructured":"27 Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131: 2745-2760.","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/annonc\/mdw072","article-title":"Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia","volume":"27","author":"28 Falchi","year":"2016","unstructured":"28 Falchi L, Vitale C, Keating MJ, et al. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Ann Oncol. 2016; 27: 1100-1106.","journal-title":"Ann Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.3389\/fimmu.2019.02832","article-title":"Long-term ibrutinib therapy reverses CD8+ T cell exhaustion in B cell chronic lymphocytic leukaemia","volume":"10","author":"29 Parry","year":"2019","unstructured":"29 Parry HM, Mirajkar N, Cutmore N, et al. Long-term ibrutinib therapy reverses CD8+ T cell exhaustion in B cell chronic lymphocytic leukaemia. Front Immunol. 2019; 10: 2832.","journal-title":"Front Immunol"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30 Szerafin L, Jak\u00f3 J, Varju L. Occurrence of associated tumours in chronic lymphocytic leukaemia. [T\u00e1rsult tumorok el\u0151fordul\u00e1sa kr\u00f3nikus lymphoid leukaemi\u00e1ban.] Orv Hetil. 2016; 157: 1752-1756. [Hungarian]","DOI":"10.1556\/650.2016.30551"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1158\/1078-0432.CCR-19-1872","article-title":"Dual targeting of CDK4\/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer","volume":"26","author":"31 Whittle","year":"2020","unstructured":"31 Whittle JR, Vaillant F, Surgenor E, et al. Dual targeting of CDK4\/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer. Clin Cancer Res. 2020; 26: 4120-4134.","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1158\/1078-0432.CCR-17-1606","article-title":"Venetoclax is effective in small-cell lung cancers with high BCL-2 expression","volume":"24","author":"32 Lochmann","year":"2018","unstructured":"32 Lochmann TL, Floros KV, Naseri M, et al. Venetoclax is effective in small-cell lung cancers with high BCL-2 expression. Clin Cancer Res. 2018; 24: 360-369.","journal-title":"Clin Cancer Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.leukres.2018.07.003","article-title":"Management of melanoma in patients with chronic lymphocytic leukemia","volume":"71","author":"33 Archibald","year":"2018","unstructured":"33 Archibald WJ, Meacham PJ, Williams AM, et al. Management of melanoma in patients with chronic lymphocytic leukemia. Leuk Res. 2018; 71: 43-46.","journal-title":"Leuk Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1080\/10428194.2019.1620941","article-title":"Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival","volume":"60","author":"34 Ishdorj","year":"2019","unstructured":"34 Ishdorj G, Beiggi S, Nugent Z, et al. Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. Leuk Lymphoma 2019; 60: 3204-3213.","journal-title":"Leuk Lymphoma"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35 Rhodes JM, LoRe VA 3rd, Mato AR, et al. Ibrutinib-associated arthralgias\/myalgias in patients with chronic lymphocytic leukemia: incidence and impact on clinical outcomes. Clin Lymphoma Myeloma Leuk. 2020; 20: 438-444.e1.","DOI":"10.1016\/j.clml.2020.02.001"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36 Poitou-Verkinder AL, Francois A, Drieux F, et al. The spectrum of kidney pathology in B-cell chronic lymphocytic leukemia\/small lymphocytic lymphoma: a 25-year multicenter experience. PLoS ONE 2015; 10: e0119156.","DOI":"10.1371\/journal.pone.0119156"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"816","DOI":"10.4103\/1319-2442.185271","article-title":"Minimal change disease: a case report of an unusual relationship","volume":"27","author":"37 Edrees","year":"2016","unstructured":"37 Edrees F, Black RM, Leb L, et al. Minimal change disease: a case report of an unusual relationship. Saudi J Kidney Dis Transpl. 2016; 27: 816-820.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38 Soldarini M, Farina L, Genderini A, et al. A rare case of atypical chronic lymphocytic leukaemia presenting as nephrotic syndrome. BMJ Case Rep. 2017; 2017: bcr-2016-218850.","DOI":"10.1136\/bcr-2016-218850"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/myc.13120","article-title":"Non-Aspergillus invasive mould infections in patients treated with ibrutinib","volume":"63","author":"39 Anastasopoulou","year":"2020","unstructured":"39 Anastasopoulou A, DiPippo AJ, Kontoyiannis DP. Non-Aspergillus invasive mould infections in patients treated with ibrutinib. Mycoses 2020; 63: 787-793.","journal-title":"Mycoses"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1182\/blood-2004-01-0207","article-title":"Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses","volume":"104","author":"40 Mangla","year":"2004","unstructured":"40 Mangla A, Khare A, Vineeth V, et al. Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood 2004; 104: 1191-1197.","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41 Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood 2015; 126: 2213-2219. [Erratum: Blood 2016; 128: 1020.]","DOI":"10.1182\/blood-2015-04-639203"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/9\/article-p336.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/9\/article-p336.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T14:49:30Z","timestamp":1698763770000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/9\/article-p336.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,28]]},"references-count":41,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.31948","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,28]]}}}